Clinical Trial: Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection
Study Status: Approved for marketing
Recruit Status: Approved for marketing
Study Type: Expanded Access
Official Title: Expanded Access Program for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options
Brief Summary: The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.
Detailed Summary:
Sponsor: Gilead Sciences
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Gilead Sciences
Dates:
Date Received: July 9, 2007
Date Started:
Date Completion:
Last Updated: July 29, 2011
Last Verified: July 2011